TrialCancer cell2022

Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.

Yasir Y Elamin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.